Xu Zhen-Zhong, Kim Yong Ho, Bang Sangsu, Zhang Yi, Berta Temugin, Wang Fan, Oh Seog Bae, Ji Ru-Rong
Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, USA.
Nat Med. 2015 Nov;21(11):1326-31. doi: 10.1038/nm.3978. Epub 2015 Oct 19.
Mechanical allodynia, induced by normally innocuous low-threshold mechanical stimulation, represents a cardinal feature of neuropathic pain. Blockade or ablation of high-threshold, small-diameter unmyelinated group C nerve fibers (C-fibers) has limited effects on mechanical allodynia. Although large, myelinated group A fibers, in particular Aβ-fibers, have previously been implicated in mechanical allodynia, an A-fiber-selective pharmacological blocker is still lacking. Here we report a new method for targeted silencing of A-fibers in neuropathic pain. We found that Toll-like receptor 5 (TLR5) is co-expressed with neurofilament-200 in large-diameter A-fiber neurons in the dorsal root ganglion (DRG). Activation of TLR5 with its ligand flagellin results in neuronal entry of the membrane-impermeable lidocaine derivative QX-314, leading to TLR5-dependent blockade of sodium currents, predominantly in A-fiber neurons of mouse DRGs. Intraplantar co-application of flagellin and QX-314 (flagellin/QX-314) dose-dependently suppresses mechanical allodynia after chemotherapy, nerve injury, and diabetic neuropathy, but this blockade is abrogated in Tlr5-deficient mice. In vivo electrophysiology demonstrated that co-application of flagellin/QX-314 selectively suppressed Aβ-fiber conduction in naive and chemotherapy-treated mice. TLR5-mediated Aβ-fiber blockade, but not capsaicin-mediated C-fiber blockade, also reduced chemotherapy-induced ongoing pain without impairing motor function. Finally, flagellin/QX-314 co-application suppressed sodium currents in large-diameter human DRG neurons. Thus, our findings provide a new tool for targeted silencing of Aβ-fibers and neuropathic pain treatment.
由通常无害的低阈值机械刺激诱发的机械性异常性疼痛是神经性疼痛的主要特征。阻断或损毁高阈值、小直径无髓鞘C类神经纤维(C纤维)对机械性异常性疼痛的作用有限。虽然此前已表明粗大的有髓鞘A类纤维,尤其是Aβ纤维,与机械性异常性疼痛有关,但仍缺乏A纤维选择性药理阻断剂。在此,我们报告了一种在神经性疼痛中靶向沉默A纤维的新方法。我们发现,Toll样受体5(TLR5)与神经丝蛋白200在背根神经节(DRG)的大直径A纤维神经元中共表达。用其配体鞭毛蛋白激活TLR5会导致膜不透性利多卡因衍生物QX-314进入神经元,从而导致主要在小鼠DRG的A纤维神经元中出现依赖TLR5的钠电流阻断。足底内联合应用鞭毛蛋白和QX-314(鞭毛蛋白/QX-314)可剂量依赖性地抑制化疗、神经损伤和糖尿病性神经病变后的机械性异常性疼痛,但在Tlr5基因敲除小鼠中这种阻断作用消失。体内电生理学研究表明,联合应用鞭毛蛋白/QX-314可选择性抑制未处理和化疗处理小鼠的Aβ纤维传导。TLR5介导的Aβ纤维阻断,而非辣椒素介导的C纤维阻断,也可减轻化疗引起的持续性疼痛,且不损害运动功能。最后,联合应用鞭毛蛋白/QX-314可抑制大直径人DRG神经元中的钠电流。因此,我们的研究结果为靶向沉默Aβ纤维和治疗神经性疼痛提供了一种新工具。